Brokerages raise target price on Lupin by up to 50%

Progress on other respiratory assets, biosimilars and resolution of warning letters will enhance medium-term growth visibility, said Kotak Institutional.

https://ift.tt/3hsA7bx

Post a Comment

0 Comments